BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  company  Roche  Registration  Ltd.  submitted  on  15  January  2001  an  application  for  Marketing 
Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for 
PEGASYS,  in  accordance  with  the  centralised  procedure  falling  within  the  scope  of  Part  A  of  the 
Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:   P. Nilsson                              Co-Rapporteur:   F. de Andres-Trelles 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
The procedure started on 30 January 2001. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on 
12 April 2001.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP 
members on 3 May 2001. 
During the meeting on 29-31 May 2001 the CPMP agreed on the consolidated List of Questions 
to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 
1 June 2001. 
The  company  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on 
9 November 2001. 
The  response  Assessment  Report  on  the  company’s  responses  to  the  List  of  Questions  was 
circulated to all CPMP members on 11 January 2002. 
During the meeting on 19-21 March 2002 the CPMP, in the light of the overall data submitted 
and the scientific discussion within the Committee, issued a positive opinion by consensus vote 
for granting a Marketing Authorisation to PEGASYS on 21 March 2002. 
1/1 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
